Received-SPF: Pass (protection.outlook.com: domain of hra.nhs.uk designates
 2a01:111:f403:c205::1 as permitted sender) receiver=protection.outlook.com;
 client-ip=2a01:111:f403:c205::1;
 helo=LO3P265CU004.outbound.protection.outlook.com; pr=C
From: no-reply-IRAS <no-reply-iras@hra.nhs.uk>
To: "sis@warwick.ac.uk" <sis@warwick.ac.uk>
Subject: IRAS 316755. Amendment
Thread-Topic: IRAS 316755. Amendment
Thread-Index: AQHc0wAx9/V1snx6BU2z6ACJQgJR7Q==
Date: Thu, 23 Apr 2026 09:04:29 +0000
Message-ID: <LO0P302MB0209A690B3032C2FCF9E8C22902A2@LO0P302MB0209.GBRP302.PROD.OUTLOOK.COM>
Accept-Language: en-GB, en-US
Content-Language: en-US
Authentication-Results-Original: dkim=none (message not signed)
 header.d=none;dmarc=none action=none header.from=hra.nhs.uk;
X-Microsoft-Antispam-Message-Info-Original: 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
X-Forefront-Antispam-Report-Untrusted: CIP:255.255.255.255;CTRY:;LANG:en;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:LO0P302MB0209.GBRP302.PROD.OUTLOOK.COM;PTR:;CAT:NONE;SFS:(13230040)(1800799024)(366016)(376014)(19092799006)(8096899003)(18002099003)(38070700021)(56012099003);DIR:OUT;SFP:1101;
X-MS-Exchange-AntiSpam-MessageData-Original-ChunkCount: 1
X-MS-Exchange-AntiSpam-MessageData-Original-0: =?us-ascii?Q?BnzMWGLwpzv220QCo2GqmUnRkL2ly/tOM0W+T4GgxNzckcKv7tyGPooi62Eg?=
 =?us-ascii?Q?KddKExY49GW1t6+BVCC/v88ocWcB/CTkxQ3hXnx0fURVp9kCA1ttbp35Kq04?=
 =?us-ascii?Q?m1CvLuH3bMTBGfNXLmClsALSXdTcbSpxVa0a+6TC3zLfUmGN1rGcEgNj+TxQ?=
 =?us-ascii?Q?IR8JJHPTxCwj9R8EGpBrPjmsb+yn/Doui0FhzKZC11QU9Ig+mzudqlM9guZh?=
 =?us-ascii?Q?+zlRJfK6zptZFZg4dyTQUIXftBlXTuN4fl3QI2aTHVGUt5HljHwj+Sni9VNh?=
 =?us-ascii?Q?ICjFekDVNSuaeasdkawF/jyQU6Ko7lr2Sxd54EYxi/nAOMlZiVxOHIAbmqxS?=
 =?us-ascii?Q?wQi0LOW+fx7ruhHzL/aIm8CtMfJpX5algQ/VDXoH0oOfaN/I/8KhXEF0SJUp?=
 =?us-ascii?Q?kZZFEileNO20BtS92eYdGnAN+aN6ImQ8oQGWX0kwcJrLpChsaXa+M9xGXR+z?=
 =?us-ascii?Q?Lj+7t0PnohzEgJXvTenY1mBNTViHRfBusG1sB8AX6LBT/NvRug9pLumG5xiM?=
 =?us-ascii?Q?u2eB7+BCzoE9NwadtCWahKHlzpxQBdjURvF4vmnbD0/i89PCbNlVIKXmFUyS?=
 =?us-ascii?Q?H7lrhQDWMNYpXpH4s2JPlgNvz3dexZe2B/XXL8RY/XZZ1ArbF8zVHpPNQDRL?=
 =?us-ascii?Q?d6vWQIu2V9MBfe1piiE9Q1O5ZVDD87tlQT4AKWn4/4aP3vsJJPOzto6VDBiA?=
 =?us-ascii?Q?j6u0Rq5KAfV1toMdjYVjcwf8cS6TC2ciBhuzPyxdEvx5B3OZ31TTI5wws9Zm?=
 =?us-ascii?Q?vKITmuXoBF1Azs7+CZxw47d574i2DGKL5tveuXkaB36URRI87B7KYrUMwYkj?=
 =?us-ascii?Q?aq/3DwFSHZTKB7TantBqxihOsRKpG+5RlQs2KhlQpko+2exmVlhPJ1w2+b2I?=
 =?us-ascii?Q?LiULCMavVDqCMNCE5xpzsvDrvHSbeIjP862ZY8qfmw/Tyn7IFQXL9Cv5h+12?=
 =?us-ascii?Q?2TRGyYyPezEk1uVIwp/4CBtE1AP+dOYv6CpNAatqt4toWXrXuB4hVYbw3FE7?=
 =?us-ascii?Q?dWKpRX6hpGpCsQjS8i9vlCGhDtVKTopoqb4vJUXhVp9Gak+NwaxWi30bNcSN?=
 =?us-ascii?Q?ZKFbN6RJo/FHdR5oIy+Uxra8XX9Nha/cCHE5mOI6kwAdIOztre//txiXFOQN?=
 =?us-ascii?Q?pwBGld6Pe9Qj+7AmZiNFmAwNY/r0lTiHdqlu3c5TEibEppnemDx5/q40UuM5?=
 =?us-ascii?Q?WmMIcKogw+iSCP/OW7OkvAOKk5eRigw7BGguM20752H7frnOEfaGyd7BDmqB?=
 =?us-ascii?Q?nBSG8JqIWvqm6a8w3GMU2dmxwZ4JYHwivPtFIf4ZYmz/YXz5c2cdWuZuqPwS?=
 =?us-ascii?Q?qKzbT2LS1M1C47nEx86MECFt9dnjsLzxSt1l3kV/f6LSmsfMrbmyXCE7pd17?=
 =?us-ascii?Q?6ZxW+kjfFcx72EL0EpSGro00TDG+n3t6QfluaPBaaLAUJA+M6q1Inoz/MCPa?=
 =?us-ascii?Q?13Sq/99aZLiLgH4oqOeiLuQeUvhWfYlwC3p0GIaLywnkoFjSEqAAfOyMQkUq?=
 =?us-ascii?Q?tNtqNP1uUNF0SHyN58tagmFGpVBtVvmpXHveA7s9yBhlOjwHS9mDYf33MkYZ?=
 =?us-ascii?Q?cd2KhIXTM+6GQffMOcn+WFWJc8iUghKHw5fx0pk6QJMYxCR094TrcJ99evWZ?=
 =?us-ascii?Q?FwhKvYEkCIioQMK9XxdBNdL6D26uNCeqvX2FCzVtZ1vXjydlYDIjwnEiYZfI?=
 =?us-ascii?Q?JW6Lp1o8A9KBpWMhOsjIZlFAkXulm5Z6T6jsqcGiIvvTquBm3DaIM759Amap?=
 =?us-ascii?Q?ygN0Uy8IJ6VqubVjAeBmHZ4cc5dv1rc=3D?=
Content-Type: multipart/alternative;
	boundary="_000_LO0P302MB0209A690B3032C2FCF9E8C22902A2LO0P302MB0209GBRP_"
X-MS-Exchange-Transport-CrossTenantHeadersStamped: CW1P302MB2076
Return-Path: no-reply-iras@hra.nhs.uk
X-MS-Exchange-Organization-ExpirationStartTime: 23 Apr 2026 09:04:33.7139
 (UTC)
X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit
X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000
X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit
X-MS-Exchange-Organization-Network-Message-Id: 04adea84-744f-4afd-182c-08dea1175649
X-EOPAttributedMessage: 0
X-EOPTenantAttributedMessage: 09bacfbd-47ef-4465-9265-3546f2eaf6bc:0
X-MS-Exchange-Organization-MessageDirectionality: Incoming
X-MS-Exchange-Transport-CrossTenantHeadersStripped: AM1PEPF000252DC.eurprd07.prod.outlook.com
X-MS-Exchange-Transport-CrossTenantHeadersPromoted: AM1PEPF000252DC.eurprd07.prod.outlook.com
X-MS-PublicTrafficType: Email
X-MS-Exchange-Organization-AuthSource: AM1PEPF000252DC.eurprd07.prod.outlook.com
X-MS-Exchange-Organization-AuthAs: Anonymous
X-MS-Office365-Filtering-Correlation-Id-Prvs: eefa016a-aec8-4c29-d1b4-08dea11753da
X-MS-Exchange-AtpMessageProperties: SA|SL
X-MS-Exchange-Organization-SCL: 1
X-Microsoft-Antispam: BCL:0;ARA:13230040|704160611799003|35042699022|12012899012|16102099003|56012099003|19002099003|18002099003|8096899003|55112099003;
X-Forefront-Antispam-Report: CIP:2a01:111:f403:c205::1;CTRY:;LANG:en;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:LO3P265CU004.outbound.protection.outlook.com;PTR:mail-uksouthazlp170100001.outbound.protection.outlook.com;CAT:NONE;SFS:(13230040)(704160611799003)(35042699022)(12012899012)(16102099003)(56012099003)(19002099003)(18002099003)(8096899003)(55112099003);DIR:INB;
X-MS-Exchange-CrossTenant-OriginalArrivalTime: 23 Apr 2026 09:04:33.6669
 (UTC)
X-MS-Exchange-CrossTenant-Network-Message-Id: 04adea84-744f-4afd-182c-08dea1175649
X-MS-Exchange-CrossTenant-Id: 09bacfbd-47ef-4465-9265-3546f2eaf6bc
X-MS-Exchange-CrossTenant-AuthSource: AM1PEPF000252DC.eurprd07.prod.outlook.com
X-MS-Exchange-CrossTenant-AuthAs: Anonymous
X-MS-Exchange-CrossTenant-FromEntityHeader: Internet
X-MS-Exchange-Transport-CrossTenantHeadersStamped: AS8PR01MB8009
X-MS-Exchange-Transport-EndToEndLatency: 00:00:01.8532819
X-MS-Exchange-Processed-By-BccFoldering: 15.20.9846.017
X-Microsoft-Antispam-Mailbox-Delivery:
	ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(930201)(20251009189)(140003)(1420198);
X-Microsoft-Antispam-Message-Info:
	=?us-ascii?Q?u07TWFO8Am5t4iKMFbAN5Fa9XG89A5h8gZPN6llS+84/vum2J77iUCh/Gje2?=
 =?us-ascii?Q?a6LxdyV8fk+3wySeI3jinKaR4kwlKjMrhw//5FodU27r+hyb03+Fg/a9iACe?=
 =?us-ascii?Q?84AE3rf1dZhxoclbk79AVMSR1CTPOC1Uk3L/oMrW85KXjy2lsric6QuF3/9i?=
 =?us-ascii?Q?YslKDhCzBQiPm7qAk5YgJJ20Mqm/33Y8LyIR3JIwq8VviLWvvujPWeto9MHC?=
 =?us-ascii?Q?nAjt8P8nHEnkdflXebx4gQ2g7dQO6jBdDedjQaZ2/+3YcS73M3zbCGPRKl6J?=
 =?us-ascii?Q?MEDEVRs1F8eniNyVH4LhLjTpvJ5lGFDkDbb9pDp7sGtDM9OaP/82yaZxU3Cs?=
 =?us-ascii?Q?3rLfDY9jwFcZR2Sm82DNqXKTscZoJEsgWCF3K/ZpMRtBak5HJOStZ5lVwmix?=
 =?us-ascii?Q?+1qmeWELcQHK6ZGfBgoTWbk5CLH5S12E/4ujxLbytR1NeXoXEiwy5Dxvw/U0?=
 =?us-ascii?Q?9rrkUFVfSWTr+8WgNs3wWFkWrk197Iu6vRRFW3xeIaEwXGf9PaTdCFXHRPk8?=
 =?us-ascii?Q?svoDsgC1UnRJde6x4E0EnKCs7rd7p2ewJg6VRsmj/ed/jvzCok633paggFO0?=
 =?us-ascii?Q?eipj58twFYwHk+avGFab8iG0Q9X+AU/FIZTBfq6ajkz5r8kalevbzi6U2bjk?=
 =?us-ascii?Q?INNVk90+Mc9Q5Zc3nXleyCwlV0so4oV+KVUp0iFwL9l72QHde7ce3PY0rvc4?=
 =?us-ascii?Q?w4oO2Xo9tERDsGBBjSciFz1mzGs/6YthlJ/dtj+3kYXcF2/YpMfBXBfubr+F?=
 =?us-ascii?Q?KxHujtZZQdicZYoCiT5/+dFlyBZ16YltsC1Sqx/K2ioFnKgQ7mRPxTpJI28+?=
 =?us-ascii?Q?4r882I/kERfdEo1C9RFFLBAkITiO1D6Pity1Q+JaixTxf74S6cegjDBwtnG6?=
 =?us-ascii?Q?MYrW/na3dNeSP6Tpelk88ilGYEX+sjndqRd6HSnNlr5d6/xynhG39xXcdaMD?=
 =?us-ascii?Q?q1iXC9cnqR8oQk7OLUlFmxhrw97GILCAZygHJyM8ln+YdXvWjXPwkdSzazcf?=
 =?us-ascii?Q?qIaYxR6PmZv+dLa8fLog7Uv7vEeYRQFUYfDtt6QISOKxKIW0F82MD3m7xYRp?=
 =?us-ascii?Q?bE6Ayqk435YZGz2rA6G2clxqceFYvtbmLBgsyTFX6xsTgoylZBculBy/Zlof?=
 =?us-ascii?Q?LnG6IAElfnJiJ9XG1a8ROw2PXhS5neDbLLZJCubk4t9pmSJj6BjIHuXT7/UF?=
 =?us-ascii?Q?bBnEuh818AFh33dFrand1jDMhujchaTMUB/Ftpo6xfo3Y2yYm+sOvYyj5FeV?=
 =?us-ascii?Q?MdTMNwxXArf+P6fOKiKPpZ9ttxzG+V/lK2RAT6/MZXRqP8DJqfp7pDTgS7Kc?=
 =?us-ascii?Q?dtOFTpR4gAgyAXvFKdjnZ77bX/I613h1l3R4K3w/eQT0UVjMWmi0BwJCC5G7?=
 =?us-ascii?Q?XbjnUIL6D7io257B+4UQSajiAwYui8JxPolCN17fFbisYhmod5i0+l3YW+6m?=
 =?us-ascii?Q?8WfQ4z6w2U3syGclyr2YMJf46+CgiejwUhQmvP4O/+t7DiJi+udTyrWDjNLn?=
 =?us-ascii?Q?8h6kP/FP/ZRxgMcrzc35nE009Uz+czKCOMI9/wBGTeBHUopHDDI3eIQyvzrj?=
 =?us-ascii?Q?Y8nUJWK/ZAYqkdmS6CfuxcOPc7WwB3SkN45Leer/cwvjKwJxRo6ni7WufuIY?=
 =?us-ascii?Q?KbTSGsyj3ivDOamwkEUVnlGdHeFt157SfQ8sAffv41yJ9Hzdkkfy2VWUozBT?=
 =?us-ascii?Q?vErddyh/oOfSMlzZcOicYrvp4otKsPTyhDTb9rdyaHkOyxiEUrQH0k9c7xUy?=
 =?us-ascii?Q?hKJiTglFo8NpQBJC66xHFGaMqyo9hjPbGjbFI6S/UlrzM1T1g0wQuofRKx1F?=
 =?us-ascii?Q?o/WgqP1SmZI61MElZx8m0E/vTu8LiWW54Xg0J+ll5hojbN/n8Tlk+Y8mvaO3?=
 =?us-ascii?Q?3jvcKFSfOpOeQeHZJclaaWUsTE/ZrQT2QCypvGeki/oCv80Z4d3xRuKKVY7X?=
 =?us-ascii?Q?c19F7vVzxTeO2WSO78Kxfw8j9/MyPnn4EqksH0cGBAGCP+Au346Ey4WL9ZDV?=
 =?us-ascii?Q?LHrYDVuNb4TSY5GOYKJA92ulCyuRT8/amWABDOYRzR+/odB+qzdkv53X2GHt?=
 =?us-ascii?Q?4gSvjNjZR3fjb/eg+c5mgoPwCyipROBfcH5C3G7tWzfPhxWyVXEnjKQJNR51?=
 =?us-ascii?Q?nWjf0VWom4fZUEBLX7TBg5r+bpfB+mfWMAgsI8qojeXa5Glz+BGDu50aciiE?=
 =?us-ascii?Q?hCwcW9HwqUWx5dtFjQuSiSdOmAIKqtuOG8wE3G7D1btJ2PU/hnq/RRTJxzAa?=
 =?us-ascii?Q?TtK2pN7JQ2ClLS++aC3CVzzOKgJhTx40HNx2W1OFilWH2+3+SS+WFhkFLCzo?=
 =?us-ascii?Q?dBB+RWYi4/CGAiVb6FKdPlQjCS/l7xEDH+Qgt3jqnB6xzWszYYl6E7TW3I35?=
 =?us-ascii?Q?f0l9MOo4vztKwGy7she1qOnleA1lpm3owf3/FK/QO1e5YJU52qDNurTkVTB8?=
 =?us-ascii?Q?sh0I7B0cbbJxqyqkCKCWv2rR65Rah0cpHcmqI//MPak0NHXHygLcUaLdbIco?=
 =?us-ascii?Q?t5FE7cReMYm6i3vLMKt4BcDrLHXJqFeRKOynOh8njD4POki8qPVd7KQP16aE?=
 =?us-ascii?Q?AIIQRA5ZN5tZGIR15bpw1stwSV9dCYvN3gJH0ByoJR1JBHgBpSYL3cmiR6Tt?=
 =?us-ascii?Q?ZWWmSl7LGMxZGxOTQPgidvPI7gQSzr/DRno+dMp1ATH9qjRtA0FvFkrgZ/Un?=
 =?us-ascii?Q?1B3KMfyRWFlVjSW9VtPm8yhopkKQG0hmlD8T8qYmnkP1MA1LpD4UQBZRMCcJ?=
 =?us-ascii?Q?23Y3NtO6IMx3o6mJ0RQmdoyq7oLoK6fAwjn6LzaWvkz3IqXt7awpPutd5WFW?=
 =?us-ascii?Q?iZBrDQiOonqah3xwUgDlylLq0k37s7RA//k=3D?=
MIME-Version: 1.0

--_000_LO0P302MB0209A690B3032C2FCF9E8C22902A2LO0P302MB0209GBRP_
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable


IRAS Project ID:                            316755
Sponsor amendment reference: NSA 25


Thank you for submitting your study amendment.  In accordance with the outc=
ome of your completed amendment tool, this amendment requires no further re=
gulatory review. Please now share this amendment with your UK research site=
s, in accordance with the instructions in your completed amendment tool.

For studies with more than one UK research site, your amendment will now be=
 automatically shared with the R&D offices of any NHS/HSC research sites in=
 Scotland, but you should share the amendment by email directly with those =
Research team/s.

For all NHS research sites in England, Wales and Northern Ireland, please n=
ow share this amendment by email directly with those sites, including both =
the R&D offices and research teams.

Do not reply to this email as this is an unmonitored address and replies to=
 this email cannot be responded to or read.

________________________________
This message may contain confidential information. If you are not the inten=
ded recipient please inform the sender that you have received the message i=
n error before deleting it. Please do not disclose, copy or distribute info=
rmation in this e-mail or take any action in relation to its contents. To d=
o so is strictly prohibited and may be unlawful. Thank you for your co-oper=
ation..
________________________________

--_000_LO0P302MB0209A690B3032C2FCF9E8C22902A2LO0P302MB0209GBRP_
Content-Type: text/html; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable

<!DOCTYPE html><html><head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3Dus-ascii"=
>
<title>IRAS 316755. Amendment</title>
</head>
<body>
<p style=3D"margin:0cm 0cm 8pt"><br>
<strong>IRAS Project ID:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &n=
bsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> 316755 &nbsp;<br>
<b>Sponsor amendment reference:&nbsp;</b>NSA 25&nbsp;<br>
<br>
<br>
<span style=3D"font-size:14px;"><span style=3D"font-family:Arial,Helvetica,=
sans-serif;"><span style=3D"line-height:normal"><span lang=3D"EN-GB">Thank =
you for submitting your study amendment.&nbsp; In accordance with the outco=
me of your completed amendment tool, this amendment
 requires no further regulatory review.&nbsp;Please now share this amendmen=
t with your UK research sites, in accordance with the instructions in your =
completed amendment tool.</span></span><br>
<br>
<span lang=3D"EN-GB"><span style=3D"line-height:107%">For studies with more=
 than one UK research site, your amendment will now be automatically shared=
 with the R&amp;D offices of any NHS/HSC research sites in Scotland, but yo=
u should share the amendment by email directly
 with those Research team/s.</span></span><br>
<br>
<span style=3D"line-height:normal"><span lang=3D"EN-GB">For all NHS researc=
h sites in England, Wales and Northern Ireland, please now share this amend=
ment by email directly with those sites, including both the R&amp;D offices=
 and research teams.</span></span><br>
<br>
<span lang=3D"EN-GB"><span style=3D"line-height:107%">Do not reply to this =
email as this is an unmonitored address and replies to this email cannot be=
 responded to or read.</span></span></span></span></p>
<hr>
This message may contain confidential information. If you are not the inten=
ded recipient please inform the sender that you have received the message i=
n error before deleting it. Please do not disclose, copy or distribute info=
rmation in this e-mail or take any
 action in relation to its contents. To do so is strictly prohibited and ma=
y be unlawful. Thank you for your co-operation..
<hr>
</body>
</html>

--_000_LO0P302MB0209A690B3032C2FCF9E8C22902A2LO0P302MB0209GBRP_--